2nd line treatment in advanced HCC and when to switch episode artwork

EPISODE · Dec 13, 2024 · 26 MIN

2nd line treatment in advanced HCC and when to switch

from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers

In the second episode of a 4-part podcast series on HCC, the Oncology Brothers, Drs Rahul and Rohit Gosain, host a podcast discussion between Dr Lorenza Rimassa and  Prof. Arndt Vogel on 2nd line treatment selection in advanced HCC and when to switch.   The discussion covers a range of topics, including 2nd line options for advanced HCC after progression on 1st line TKIs and IO-based therapies, as well as:   •          How to approach sequencing in clinical practice •          The available data supporting sequencing strategies •          When to switch to 2nd line therapy and what to consider when doing so   This is the second video podcast episode in a 4-part series. Access the rest of the series here: Part 1 - The use of IO in unresectable HCC Part 3 - Intermediate HCC: treatment options and strategies (coming soon) Part 4 - The evolving role of IO in intermediate HCC (coming soon)   Clinical takeaways   •          Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions •          When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life. •          Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered •          Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management •          Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation.   Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!   Website: http://www.oncbrothers.com/   X/Twitter: https://twitter.com/oncbrothers   Contact us at [email protected]

In the second episode of a 4-part podcast series on HCC, the Oncology Brothers, Drs Rahul and Rohit Gosain, host a podcast discussion between Dr Lorenza Rimassa and  Prof. Arndt Vogel on 2nd line treatment selection in advanced HCC and when to switch.   The discussion covers a range of topics, including 2nd line options for advanced HCC after progression on 1st line TKIs and IO-based therapies, as well as:   •          How to approach sequencing in clinical practice •          The available data supporting sequencing strategies •          When to switch to 2nd line therapy and what to consider when doing so   This is the second video podcast episode in a 4-part series. Access the rest of the series here: Part 1 - The use of IO in unresectable HCC Part 3 - Intermediate HCC: treatment options and strategies (coming soon) Part 4 - The evolving role of IO in intermediate HCC (coming soon)   Clinical takeaways   •          Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions •          When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life. •          Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered •          Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management •          Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation.   Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!   Website: http://www.oncbrothers.com/   X/Twitter: https://twitter.com/oncbrothers   Contact us at [email protected]

NOW PLAYING

2nd line treatment in advanced HCC and when to switch

0:00 26:18

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Destiny Architecture® Meditations Heather Larson Bring your mediation practice into the Valueverse. Solving for Change MOBIA Technology Innovations Solving for Change welcomes business and technology leaders to share stories of bold business transformation within complex organizations. In an era when technology and markets are changing around businesses, the key to staying competitive is to evolve in response to those changes.  MOBIA’s Mike Reeves and Marc LeBlanc investigate business transformation, deconstructing the challenges, ambitions, and market disruptions that drive companies to embark on transformation journeys, and exploring their unique approaches to achieving meaningful outcomes.  What sparks leaders to pursue business transformation? How do they overcome the challenges along the way? What are the keys to creating enduring change?  Through in-depth conversations with business and technology leaders, Mike and Marc answer these questions and explore how businesses evolve by pulling four key transformation levers: people, process, technology, and culture. The Lee Olsen Show Lee Olsen CJF I want to help you improve all areas of your life by 3 types of podcasts!👉Blood, Sweat & Blessings-Interviews of normal people that have achieved BIG things!👉Series!!! For Love of the Horse- Brad Jackman DVM & Lee Olsen CJF, how to help your horse!👉Business Tips- Proven Life Changing Business Strategies with Lee Olsen Darknet Discussions Darknet Discussions Welcome to "Darknet Discussions," the podcast that gets into the shadows of the internet to bring you the most intriguing, enlightening, and sometimes unsettling stories from the dark web. Hosted by seasoned darknet aficionados, each episode of "Darknet Discussions" explores the intricate dynamics of darknet markets, cybersecurity threats, and the digital underworld. Join us as we interview experts, discuss the latest trends in cybercrime, and shed light on the technologies that operate beneath the surface of everyday internet use. Also, we occasionally go off on a tangent about something completely unrelated.

Frequently Asked Questions

How long is this episode of Oncology Brothers: Practice-Changing Cancer Discussions?

This episode is 26 minutes long.

When was this Oncology Brothers: Practice-Changing Cancer Discussions episode published?

This episode was published on December 13, 2024.

What is this episode about?

In the second episode of a 4-part podcast series on HCC, the Oncology Brothers, Drs Rahul and Rohit Gosain, host a podcast discussion between Dr Lorenza Rimassa and  Prof. Arndt Vogel on 2nd line treatment selection in advanced HCC and when to...

Can I download this Oncology Brothers: Practice-Changing Cancer Discussions episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!